Effect of type 2 diabetes mellitus on efficacy and safety of therapeutic apheresis for severe hypertriglyceridemia.

Autor: Bagir GS; Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Teaching and Medical Research Center, Adana, Turkey., Bakiner OS; Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Teaching and Medical Research Center, Adana, Turkey., Haydardedeoglu FE; Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Teaching and Medical Research Center, Adana, Turkey., Araz F; Department of Gastroenterology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Teaching and Medical Research Center, Adana, Turkey., Ertorer ME; Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Teaching and Medical Research Center, Adana, Turkey., Kozanoglu İ; Department of Physiology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Teaching and Medical Research Center, Apheresis Unit, Adana, Turkey.
Jazyk: angličtina
Zdroj: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy [Ther Apher Dial] 2021 Oct; Vol. 25 (5), pp. 681-686. Date of Electronic Publication: 2020 Dec 13.
DOI: 10.1111/1744-9987.13603
Abstrakt: The efficacy and safety of triglyceride (TG) apheresis in patients with type 2 diabetes mellitus (DM) is unclear. Diabetic complications may predispose patients to adverse events (AEs) associated with the apheresis procedure, and diabetic dyslipidemia may negatively affect the efficacy of therapeutic apheresis (TA). We investigated the effect of DM on the efficacy and complications of TA. Patients with severe hypertriglyceridemia who underwent apheresis for treatment or for the prevention of acute pancreatitis were included in this retrospective study. Epidemiological data, lipid parameters, and AEs were recorded before and after each therapeutic session. A total of 166 procedures were performed in 27 patients. Group 1 included 17 patients with type 2 DM, and Group 2 included 10 patients without DM. The mean percentage decrease in TG levels (TG%) was higher in Group 1 (71.9% vs 60.6%, P < .001). The TG% was negatively correlated with the duration of DM in Group 1 (r = -.49, P < .001). The total number of TA sessions was 142 in patients who underwent double filtration plasmapheresis and 24 in patients who underwent therapeutic plasma exchange. We observed 9 (5.4%) mild-to-moderate AEs. No intergroup difference was observed in the total number of AEs (P = .06). TA is safe and effective in patients with type 2 DM with severe hypertriglyceridemia.
(© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.)
Databáze: MEDLINE
Externí odkaz: